The relationship between serum resolvin D1, NLRP3, cytokine levels, and adolescents with first-episode medication-na?ve major depressive disorder

作者全名：Guo, Jiamei; Zhang, Tanwei; Chen, Wanjun; Tan, Jianyu; Li, Xiao; Zheng, Anhai; Fu, Yixiao; Qiu, Tian

作者地址：[Guo, Jiamei; Zhang, Tanwei; Chen, Wanjun; Tan, Jianyu; Li, Xiao; Zheng, Anhai; Fu, Yixiao; Qiu, Tian] Chongqing Med Univ, Affiliated Hosp 1, Dept Psychiat, Chongqing 400016, Peoples R China

通信作者：Qiu, T (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Psychiat, Chongqing 400016, Peoples R China.

来源：BMC PSYCHIATRY

ESI学科分类：PSYCHIATRY/PSYCHOLOGY

WOS号：WOS:001204510100003

JCR分区：Q2

影响因子：3.4

年份：2024

卷号：24

期号：1

开始页：　

结束页：　

文献类型：Article

关键词：Major depressive disorder; Adolescent; Resolvin D1; NLRP3; Cytokines; Medication-naive

摘要：Background Inflammation has become a critical pathological mechanism of Major Depressive Disorder (MDD). NLRP3 is a critical inflammatory pathway to maintain the immune balance. Recently, preclinical evidence showed that Resolvin D1 might potentially offer a new option for antidepressant treatment due to its protective effects through the inhibition of neuroinflammation. However, whether they have clinical value in the diagnosis and treatment evaluation of adolescent depression was unclear.Methods Forty-eight untreated first-episode adolescent patients with moderate to severe major depressive disorder, as well as 30 healthy adolescents (HCs, age and gender-matched), were enrolled for this study. Their ages ranged from 13 to 18 (15.75 +/- 1.36) years. The patients were treated with fluoxetine for 6-8 weeks. HDRS-17 was used to evaluate the severity of depressive symptoms. Venous blood samples were collected at baseline for the two groups and at the time-point of post-antidepressant treatment for the patients. Serum concentrations of RvD1, NLRP3, IL-1 beta, IL-18, and IL-4 were measured by enzyme-linked immunosorbent assays (ELISA) pre- and post-fluoxetine treatment.Results Serum levels of RvD1 and anti-inflammatory cytokine IL-4 were significantly elevated in adolescents with MDD compared to healthy adolescents, but no significant difference in NLRP3, IL-1 beta, and IL-18 between the two groups. Meanwhile, RvD1 (positively) and IL-4 (negatively) were correlated with the severity of symptoms (HDRS-17 scores) after adjusting age, gender, and BMI. Interestingly, fluoxetine treatment significantly reduced the serum levels of RvD1, NLRP3, IL-1 beta, and IL-18 in MDD adolescents but increased the levels of IL-4 relative to baseline. Furthermore, we observed that serum levels of RvD1 might be an excellent distinguishing indicator for depression and healthy adolescents.Conclusions Our study is the first to compare RvD1 and NLRP3 between adolescent MDD and HCs. Our findings of reactive increase of RvD1 in adolescent MDD comprised a novel and critical contribution. Our results showed the presence of inflammation resolution unbalanced in adolescents with MDD and indicated that RvD1 might be an ideal biomarker for diagnosing and treating adolescent MDD.

基金机构：Chongqing Science and Health Joint Medical Scientific Research Project

基金资助正文：We want to thank all the adolescents for attending the evaluation of mental health and blood sample collection.